Company Overview and News
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
KMI.WS ECOR PLNT KMI.PRA PKG AEP NINE ADT GE COF-P GILD TMUS PDYPF SYF XERS JNJ VZ MSFT ADS KZR NNN EIDX FB RF.PRB AVRO RF.PRA HOPE NFLX AXP EHC BAC COF-D SEAS COF-C COF-F KR KS IIIV PNFP AAPL DDOC AEP.PRA SJM INPAP SIX JPM GNE WRK LGEJY KMRFZ DE 39IB KMX COF.WS RF UAL WMT CFIN LGEAF IP AMZN MGTA NTRS HON KMI CIWV GM.WS.A GM.WS.B HCSG GM.WS.C KMR CVB VLKAY LGEIY EBAY EPRT STT SLB BAC DFS LGEPF STM BBY BX BK STM LTXB LGLD SLB GM.WSB FOXA CLW COF.PRG COF.PRH PM STT.PRC STT.PRE NTRSP STT.PRD STT.PRG AUTL COF.PRP DLPH SWKS GS SWK TRTX GM PII COF.PRC COF.PRD DIS NEE COF.PRF IBM MOR F GEC C CMCSA COF FUN FUL CFG HBAN NEE.PRI XEL NEE.PRJ TGT BLK S PPG T NEE.PRC NEE.PRQ NEE.PRR SNE DPZ
43 of 101 S&P 500 Index top-yield dividend stocks were labeled as "safer" for dividends because they showed positive 1-year returns and free cash-flow yields greater than their dividend yields as of 7/9/18.
DLR.PRH DLR.PRG HCN PM DLR.PRJ PFG DLR.PRI WELL.PRI O.PRF MET STX OPRF PRU VZA IP CUKPF CCL WELL ABBV VTR PRU F INPAP PFK O CCL HCN.PRJ CUK HCN.PRI SPG.PRJ PRH CVX VZ VTRB SPG ABBV DLR QCOM DLR.PRC DLR.PRF PJH IVZ
WASHINGTON (Reuters) - The U.S. Environmental Protection Agency’s acting chief said on Wednesday he would push to cut regulations on industry and speed up decisions on permits, echoing the policies of former head Scott Pruitt who stepped down last week.
XEL IP INPAP ADM
But recently, the equity research team at Goldman compiled a list of stocks within the company’s coverage universe that have the most potential upside to their price targets. The list is long (about 40 stocks), and Goldman pegs all of them as having roughly 30% or more upside to their price target.
LRCX CAT RCL NVDA MAR.WI CFIN NOC TSNU IP JEC CIWV TSN NCLH SCHW.PRBCL TDG INPAP DWDP CFG MAR SCHW MU BWA HRS WRK DE
Designed to provide broad exposure to the Materials - Timber segment of the U.S. equity market, the Invesco MSCI Global Timber ETF (CUT - Free Report) is a passively managed exchange traded fund launched on 11/09/2007.
ARKG IP INPAP CVRR ARKK
International Paper Company (IP - Free Report) looks promising at the moment, backed by its focus on acquisitions and restructuring initiatives. We believe that this is the right time to add the stock to your portfolio, as it is poised to carry the bullish momentum ahead. Let's delve deeper and analyze the factors that make this paper and packaging company an attractive investment option. What's Working in Favor of International Paper? Solid Rank & VGM Score: International Paper currently carries a Zacks Rank #2 (Buy).
IP INPAP MEOH
However, pressure from increasing debts, expensive pension plans, and weakness in the containerboard segment along with various other factors may lead to an underwhelming Q2.
IP INPAP WRK
Amazon.com, Inc. (AMZN - Free Report) ,Although diversified, its core business is primarily an online retailer of consumer products and subscriptions in North America and internationally. This Zacks #1, Strong Buy, benefits from an expanding AWS enterprise customer base and increasing number of paid Prime members. It generates a strong cash flow. The company’s stock has posted solid gains, outperforming its industry on a year-to-date basis.
AMZN IP HFC INPAP KHC RCKY
1h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
22h - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
2018-07-13 - Asif
Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...
Silicon Investor Message Boards
This table lists all message boards related to IP / International Paper Company on message board site Silicon Investor.
as of ET